Weight Management

Orforglipron

LY3502970 · ATTAIN trial · oral non-peptide GLP-1

Lilly oral small-molecule GLP-1R agonist (LY3502970), not a peptide and not Rybelsus. Phase 3 ATTAIN. Do not put it in the reconstitution calculator.

Not FDA-approved - research chemical
Reviewed by CalcMyPeptide Editorial Team
Last updated: August 2026Evidence: Emerging1 peer-reviewed citation
Typical research dose
12-36-45 mg/day (oral)
Frequency
1× daily (oral)
Half-life
~11 hours (oral, once daily)
Common vials
N/A (oral)
Molecular weight
~400–500 Da

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

  • Metabolic / weight7.5/10

    Phase 3 ATTAIN oral small-molecule program. Ceiling 8 for Phase 2–3. Not a peptide vial. Not Rybelsus (which is oral semaglutide + SNAC).

Compound card

Sequence
Non-peptide small-molecule GLP-1R agonist (LY3502970)
Class
Once-daily oral GLP-1 (not a peptide; no reconstitution)
Formula
Small molecule (non-peptide)
Status
Not FDA-approved · research use

How it works

Orforglipron (LY3502970) is a non-peptide, small-molecule oral GLP-1 receptor agonist developed by Eli Lilly. Unlike semaglutide's oral form (Rybelsus, which requires a complex absorption enhancer and strict fasting), orforglipron is a small molecule taken orally without food restrictions. Phase 3 ATTAIN trials showed 9.4% body weight reduction over 40 weeks. Its oral convenience and no-fasting requirement could make it a preferred access point for GLP-1 therapy globally.

Source: PMID: 37351564 (Phase 2 NEJM)

Goal context

Pill is not a peptide SKU

This page lives in the GLP-1 filter because the receptor is GLP-1R. The molecule is not an amino-acid chain. The calculator is the wrong tool.

Research Use Cases

  • ✓Pill is not a peptide SKU

Dosing

PhaseDoseFrequencyNotes
Phase 3 Doses3 mg / 12 mg / 36 mgOnce daily (oral)No food restrictions required - differentiator vs Rybelsus (semaglutide oral).

Administration

Route / form
Oral (capsule/tablet)
Timing
Once daily, any time, with or without food.
Empty stomach?
No - Food timing is not critical.

Timeline

Month 1-3
Appetite suppression and early weight loss.
Month 6-12
Phase 3: ~9.4% body weight reduction at highest dose over 40 weeks.

Who it is for

Obesity (Needle-Free)

High

Phase 3 data: 9.4% BWL. Key advantage - no injection required. Ideal for injection-averse patients.

Type 2 Diabetes

High

Phase 3 ATTAIN-T2DM: HbA1c reduction of 1.7% at 36 mg.

Safety & Considerations

Investigational - not FDA-approved as of early 2026. GI side effect profile consistent with GLP-1 class. NDA filing anticipated 2025-2026. No injection; no fasting window required.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

  • ATTAIN describes tablets in a trial, not a compounded capsule of unknown fill.
  • No vial in this database. Oral small molecule. SubQ math does not apply.
  • Not FDA-approved as a finished product on this leaf’s date.

Verdict

Orforglipron is Lilly’s oral small-molecule GLP-1, not a lyophilized peptide. Do not put it in the reconstitution calculator. It is not Rybelsus and not a research cake.

Interactions & Contraindications

Investigational - not FDA-approved as of early 2026. GI side effect profile consistent with GLP-1 class. NDA filing anticipated 2025-2026. No injection; no fasting window required.

Frequently Asked Questions

How is orforglipron different from oral semaglutide (Rybelsus)?▼
Orforglipron is a true small molecule - no food or timing restrictions. Rybelsus (oral semaglutide) must be taken on empty stomach with ≤120mL water 30 min before eating. Orforglipron also doesn't require an absorption enhancer tablet.
Is orforglipron FDA-approved?▼
Not yet as of 2026. Phase 3 ATTAIN trials have reported results; FDA submission expected. Eli Lilly has stated submission is anticipated in 2025-2026.

References

  1. Dahl D et al. “"Orforglipron for obesity (Phase 3 ATTAIN)".” New England Journal of Medicine (2024).

📚 Related Articles

GLP-1 Dose Escalation Guide: Semaglutide, Tirzepatide & Retatrutide
14 min read • Pillar Guide

Looking for a trusted source? See our recommended suppliers

Independently tested · COA-verified · Save 10% with our exclusive code

See suppliers →
← Back to Peptide Library